Systemic Lupus Erythematosus Market, By Drug Classes (NSAIDs, Corticosteroids, Antimalarials, Immunosuppressants, and Biologics), By Route of Administration (Oral, Intravenous, and Subcutaneous), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis, and Forecast till 2029

The systemic lupus erythematosus market accounted for US$ 1.87 billion in 2019 and is estimated to be US$ 3.6 billion by 2029 and is anticipated to register a CAGR of 7.0%.

Systemic lupus erythematosus (SLE) is the chronic, autoimmune disorder which involves several organ-systems such as kidney, heart, blood, skin, joints, and lungs in most severe cases, brain. In this disease, the human immune system converts hyperactive and attacks the healthy, normal tissues of the body. SLE can often result in symptoms such as malar rash, sub-acute cutaneous lesions, discoid lesions, arthritis, photosensitivity, oral ulcers, serositis, nephropathy, thrombocytopenia, haemolytic anemia, neurologic involvement, fever, thrombosis, Raynaud’s phenomenon, livedo reticularis, and myositis. The systemic lupus erythematosus market accounted for US$ 1.87 billion in 2019 and is estimated to be US$ 3.6 billion by 2029 and is anticipated to register a CAGR of 7.0%.

Impact of COVID-19 on the market

In an attempt to come up with a reliable treatment for Covid-19, multiple therapeutic regimens are being followed across the world. One of the treatment includes the use of hydroxychloroquine. Whereas, a second treatment line focuses to use antiviral drugs used in the disease management of HIV. Both these methodologies have rushed the demand from advanced antimalarial and antivirals drugs. However, the WHO has not prescribed any of these methods at the moment, neither have they commented if one is better than the other. This report will quantify the impact of this pandemic on the systemic lupus erythematosus market.

According to the National Institute of Arthritis and Musculoskeletal and Skin Diseases, the occurrence of this disease is higher in the African-American and Asian populations. Women from the Asian, Afro-Caribbean and Hispanic descent are primarily affected by this disease. Over the past few decades, the SLE drugs market has observed a paradigm shift from generic and off label drugs to advanced innovator drugs with improved delivery options. Previously, the market was fortified with multiple drugs administered through conventional routes such as oral, intravenous and topical formulations. Nevertheless, the recent launch of a subcutaneous formulation of existing drug namely, Benlysta has resulted in the unmet requirement for the efficient and better innovator drugs with a convenient mode of delivery. Moreover, the systemic lupus erythematosus market would grow prominently over the forecast period owing due to factors such as rising ageing population, growing incidences of SLE, and increasing R&D investment on SLE drugs.

Conversely, factors hampering the target market growth are growing drugs prices and the presence of a stringent regulatory environment.

The systemic lupus erythematosus market is segmented based on the drug classes, route of administration, and region.

On the basis of the drug classes, the systemic lupus erythematosus market is segmented into NSAIDs, corticosteroids, antimalarials, immunosuppressants, and biologics. Based on the route of administration, the target market is classified into oral, intravenous, and subcutaneous.

Regional Insights:

In the region, the systemic lupus erythematosus market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America leads the market in 2019, with the U.S. at the leading position. The region is expected to maintain its dominance over the forecast period. Higher prevalence of SLE along with coverage for speciality drugs and improved healthcare infrastructure is driving to the growth of the regional market. Europe holds a second-highest regional market position in 2019, owing to five major European Union countries (Germany, U.K., Italy, Spain, and France) were the first to approve Benlysta as an add-on therapy for the treatment of active SLE. Moreover, due to improved coverage policies, there is greater adoption of belimumab since it is present in both formulations. Asia Pacific, Latin America, and Middle East & Africa remains behind due to low prominence in the market. Low revenue generation in these regions can be recognized due to the several factors, including low rheumatologist to population ratio, which prevents treatment and diagnosis at an early stage.

Attribute	Details
The base year for estimation	2020
Forecast period	2020 – 2029
Market representation	Revenue in USD Million & CAGR from 2020 – 2029
Market Segmentation	By Drug Classes - NSAIDs, Corticosteroids, Antimalarials, Immunosuppressants, and Biologics By Route of Administration – Oral, Intravenous, and Subcutaneous
Regional scope	North America - U.S., Canada Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at , regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2020 to 2029.  For the purpose of this study, has segmented the systemic lupus erythematosus market report based on drug classes, route of administration, and region.

Systemic Lupus Erythematosus Market, By Drug Classes:

• NSAIDs
• Corticosteroids
• Antimalarials
• Immunosuppressants
• Biologics

Systemic Lupus Erythematosus Market, By Route of Administration:

• Oral
• Intravenous
• Subcutaneous

The key players operating in the systemic lupus erythematosus market include GlaxoSmithKline, Novartis, Roche, Bayer, Pfizer, Sanofi, F. Hoffmann-la Roche Ltd., Hadasit medical research services and development, Hansa medical ab, and Harbor biosciences. GlaxoSmithKline in collaboration with Roche is leading clinical trials with Benlysta and rituximab to regulate their combined efficacy in treating severe symptoms of SLE. Additionally, Novartis developed biosimilar rituximab at a low cost, which is utilized as an off label drug to drive the adoption of biological therapies in emerging regions.

• GlaxoSmithKline
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Overview
  • Business Strategies

• Novartis
• Roche
• Bayer
• Pfizer
• Sanofi
• F. Hoffmann-la Roche Ltd.
• Hadasit Medical Research Services and Development
• Hansa Medical Lab
• Harbor Biosciences

“*” marked represents similar segmentation in other categories in the respective section

1. Research Objective and Assumption
   • Preface
   • Research Objectives
   • Study Scope
   • Years Considered for the study
   • Assumptions
   • Abbreviations
2. Research Methodology
   • Research data
   • Primary Data
     • Primary Interviews
     • Primary Breakdown
     • Key data from Primary Drug Classess
     • Key Thickness Insights
   • Secondary Data
     • Major Secondary Drug Classess
     • Secondary Drug Classess
   • Market Estimation
   • Top-Down Approach
     • Approach for estimating Market Share by Top-Down Analysis (Supply Side)
   • Bottom-Up Approach
     • Approach for estimating market share by Bottom-up Analysis (Demand Side)
   • Market Breakdown and Data Triangulation
   • Research Assumptions
3. Market Purview
   • Executive Summary
   • Key Findings—Global Outlook for Systemic Lupus Erythematosus Strategies
     • Key Questions this Study will Answer
     • Market Snippet, By Drug Classes
     • Market Snippet, By Route of Administration
     • Market Snippet, By Region
   • Opportunity Map Analysis
   • Executive Summary—3 Big Predictions
4. Market Dynamics, Regulations, and Trends Analysis
   • Market Dynamics
     • Drivers
     • Restraints
     • Market Opportunities
     • Market Trends
   • DR Impact Analysis
   • PEST Analysis
   • Porter’s Five Forces Analysis
   • Opportunity Orbit
   • Market Investment Feasibility Index
   • Macroeconomic Factor Analysis
5. Market Segmentation, By Drug Classes, 2019 – 2029, (US$ Mn)
   • Overview
     • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2019 – 2029
     • Y-o-Y Growth Analysis (%), 2019 – 2029
     • Segment Trends
   • NSAIDs
     • Overview
     • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2019 – 2029
   • Corticosteroids
     • Overview
     • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2019 – 2029
   • Antimalarials
     • Overview
     • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2019 – 2029
   • Immunosuppressants
     • Overview
     • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2019 – 2029
   • Biologics
     • Overview
     • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2019 – 2029
6. Market Segmentation, By Route of Administration, 2019 – 2029, (US$ Mn)
   • Overview
     • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2019 – 2029
     • Y-o-Y Growth Analysis (%), 2019 – 2029
     • Segment Trends
   • Oral
     • Overview
     • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2019 – 2029
   • Intravenous
     • Overview
     • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2019 – 2029
   • Subcutaneous
     • Overview
     • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2019 – 2029
7. Global Market, By Region, 2019 – 2029, (US$ Mn)
   • Overview
     • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2019 – 2029
     • Y-o-Y Growth Analysis (%), 2019 – 2029
     • Regional Trends
   • North America
     • Market Size and Forecast (US$ Mn), By Drug Classes, 2019 – 2029
     • Market Size and Forecast (US$ Mn), By Route of Administration, 2019 – 2029
     • Market Size and Forecast (US$ Mn), By Country, 2019 – 2029
       • U.S.
       • Canada
   • Europe
     • Market Size and Forecast (US$ Mn), By Drug Classes, 2019 – 2029
     • Market Size and Forecast (US$ Mn), By Route of Administration, 2019 – 2029
     • Market Size and Forecast (US$ Mn), By Country, 2019 – 2029
       • Germany
       • UK
       • France
       • Russia
       • Italy
       • Rest of Europe
   • Asia Pacific
     • Market Size and Forecast (US$ Mn), By Drug Classes, 2019 – 2029
     • Market Size and Forecast (US$ Mn), By Route of Administration, 2019 – 2029
     • Market Size and Forecast (US$ Mn), By Country, 2019 – 2029
       • China
       • India
       • Japan
       • South Korea
       • Rest of Asia Pacific
   • Latin America
     • Market Size and Forecast (US$ Mn), By Drug Classes, 2019 – 2029
     • Market Size and Forecast (US$ Mn), By Route of Administration, 2019 – 2029
     • Market Size  and Forecast (US$ Mn), By Country, 2019 – 2029
       • Brazil
       • Mexico
       • Rest of Latin America
   • Middle East & Africa
     • Market Size and Forecast (US$ Mn), By Drug Classes, 2019 – 2029
     • Market Size and Forecast (US$ Mn), By Route of Administration, 2019 – 2029
     • Market Size and Forecast (US$ Mn), By Country, 2019 – 2029
       • GCC
       • Israel
       • South Africa
       • Rest of Middle East
8. Competitive Landscape
   • Heat Map Analysis
   • Market Presence and Specificity Analysis
9. Company Profiles
   • • GlaxoSmithKline
       • Company Overview
       • Product Portfolio
       • Key Highlights
       • Financial Overview
       • Business Strategies
     • Novartis
     • Roche
     • Bayer
     • Pfizer
     • Sanofi
     • F. Hoffmann-la Roche Ltd.
     • Hadasit Medical Research Services and Development
     • Hansa Medical Lab
     • Harbor Biosciences
10. The Last Word
    • Future Impact
    • About Us
    • Contact